Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.

Drug metabolism and disposition: the biological fate of chemicals - 1 Dec 2009

Backman Janne T, Honkalammi Johanna, Neuvonen Mikko, Kurkinen Kaisa J, Tornio Aleksi, Niemi Mikko, Neuvonen Pertti J

Abstract excerpt

Gemfibrozil 1-O-beta-glucuronide is a mechanism-based inhibitor of cytochrome P450 2C8. We studied the recovery of CYP2C8 activity after discontinuation of gemfibrozil treatment using repaglinide as a probe drug, to estimate the in vivo turnover half-life of CYP2C8. In a randomized five-phase crossover study, nine healthy volunteers ingested 0.25 mg of repaglinide alone or after different time intervals after a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cross-Over Studies
Share to Cytochrome P-450 CYP2C8

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucuronates

Share to Half-Life

Share to Hypolipidemic Agents

Share to Liver-Specific Organic Anion Transporter 1

Share to Molecular Probes

Share to Organic Anion Transporters

Source

Identifiers

PMID: 19773535
DOI: 10.1124/dmd.109.029728

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.PMID 19773535Read ↗

Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses.Semantic proximity Read ↗

Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses.Semantic proximity Read ↗

Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.Semantic proximity Read ↗

Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide.Semantic proximity Read ↗

Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.Semantic proximity Read ↗

CYP3A4 genetic polymorphism influences repaglinide's pharmacokinetics.Semantic proximity Read ↗

The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.Semantic proximity Read ↗

Cyclosporine markedly raises the plasma concentrations of repaglinide.Semantic proximity Read ↗

The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.Semantic proximity Read ↗

Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study.Semantic proximity Read ↗

Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast.Semantic proximity Read ↗

Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.